FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in focal therapy of prostate cancer. Method involves administering composition containing 2.5 mg or 15 mg of fexapotide triflutate (FT) and neutral buffered saline, by intra-prostate injection directly into low-grade prostate cancer.
EFFECT: use of the invention enables to reduce the incidence of malignant tumour, the degree of malignant tumour and the progression of the malignant tumour in the entire half of the prostate where the initial single-focal cancer was found and treated.
8 cl, 8 tbl, 4 ex
